Eli Lilly Stock Hits Record as Foundayo Nears European Approval; Valuation Surpasses Berkshire Hathaway
What’s happening
Eli Lilly (LLY) reached an all-time high as Foundayo, an oral obesity pill, neared European regulatory approval. The company posted 47.7% revenue growth driven by weight-loss drug adoption, and LLY's market capitalization surpassed Berkshire Hathaway. Goldman Sachs expects Lilly to beat Q3 earnings and raise guidance.
Market impact
LLY's ascent reflects investor conviction in the obesity drug market's scale and Lilly's execution. Foundayo approval expands addressable market beyond injectable GLP-1 agonists, reducing patient barriers to entry. Competitors Novo Nordisk and Amgen edge higher but face margin pressure from Lilly's aggressive pricing and pipeline depth.
Broader implications
Lilly's rise signals a structural shift in pharmaceutical valuations toward obesity and metabolic disease. The obesity drug market could exceed $100 billion annually, reshaping healthcare spending and pharma capital allocation for the next decade.
Sources (3)
The articles Pulse read to write this story- Eli Lilly Rises 4% While Foundayo Nears European Approval; Amgen and Novo Nordisk Edge Higher247wallst.comStrong bullish +80
LLY Stock Hits New Record, Eli Lilly Valuation Pushes Past Berkshire Hathaway Ahead Of Q3 Earningsfinance.yahoo.comStrong bullish +88
If Eli Lilly Grows At 10% a Year, Here's What $1,000 Becomes By 2030aol.comBullish +22
Written by Pulse AI from the articles above. Always check the original reporting before acting on it.